

Technology Appraisal Committee Meeting (Committee A)
10 Spring Gardens, London SW1A 2BU

Minutes: Confirmed

Date and Time: Tuesday 17 April 2018, 10:00 – 14:00

Present:	1. Dr Jane Adam (Chair)	Present for all notes
	2. Professor Iain Squire (Vice-Chair)	Present for all notes
	3. Dr Graham Ash	Present for all notes
	4. Dr Justin Daniels	Present for all notes
	5. Dr Steve Edwards	Present for all notes
	6. Dr Rita Faria	Present for all notes
	7. Dr Rachel Hobson	Present for all notes
	8. Ms Pamela Rees	Present for all notes
	9. Dr Paul Robinson	Present for all notes
	10. Ms Ellen Rule	Present for all notes
	11. Dr Brian Shine	Present for all notes
	12. Dr John Watkins	Present for all notes
	13. Professor Olivia Wu	Present for all notes
	14. Dr Mohit Sharma	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Sana Khan	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Eleanor Donegan	Technical Adviser, National Institute for Health and Care Excellence	Present for all notes
Max Barnish	Peninsula Technology Assessment Group (PenTAG), Evidence Review Group	Present for notes 1 to 8

Linda Long	Peninsula Technology Assessment Group (PenTAG), Evidence Review Group	Present for notes 1 to 8
Irina Tikhonova	Peninsula Technology Assessment Group (PenTAG), Evidence Review Group	Present for notes 1 to 8
Dr Shuaib Nasser	Consultant Physician in Allergy & Asthma, Clinical Expert	Present for notes 1 to 8
Prof. Tim Harrison	Professor of Asthma & Respiratory Medicine/Honorary Consultant, Clinical Expert	Present for notes 1 to 8
Lehanne Sergison	Patient Expert	Present for notes 1 to 8
Dr Samantha Walker	Patient Expert	Present for notes 1 to 8

Non-public attendees:

Chloe Kastoryano	Public Involvement Adviser, NICE	Present for all notes
Juliet Kenny	Technical Analyst, NICE	Present for all notes
Hamish Lunagaria	Technical Analyst, NICE	Present for all notes
Ria Skelton	Editor, NICE	Present for all notes
Adam Storrow	Business Analyst, NICE	Present for all notes
Ana Uribe-Ucheverry	Corporate Office Coordinator, NICE	Present for all notes
Neel Ocean	Peninsula Technology Assessment Group (PenTAG), Evidence Review Group	Present for notes 1 to 8
Segun Bello	Peninsula Technology Assessment Group (PenTAG), Evidence Review Group	Present for notes 1 to 8

Notes

Any other Business

1. None.

Minutes from the last meeting

2. The committee approved the minutes of the committee meeting held on 14 March 2018.

Appraisal of benralizumab for treating severe eosinophilic asthma [ID1129]

Part 1 – Open session

3. The Chair welcomed the invited clinical and patient experts, evidence review group (ERG) representatives and representatives from AstraZeneca.
4. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
 - 4.1. Dr Shuaib Nasser declared a personal specific financial interest as he has been on advisory boards for GlaxoSmithKline, Novartis and TEVA. He has provided lectures for AstraZeneca and Novartis. He has also undertaken clinical trials for AstraZeneca on benralizumab and for GlaxoSmithKline for mepolizumab and received no direct payment for these.
 - 4.1.1. It was agreed that this declaration would not prevent participation in this section of the meeting.
 - 4.2. Professor Tim Harrison declared a personal specific financial interest as he has received payments from AstraZeneca for two advisory boards related to benralizumab. His institution has received funds for research trials from AstraZeneca.
 - 4.2.1. It was agreed that this declaration would not prevent participation in this section of the meeting.
 - 4.3. No further conflicts of interest were declared for this appraisal.
5. The Chair introduced the lead team, Rachel Hobson, Pamela Rees and Rita Faria, who gave presentations on the clinical effectiveness and cost effectiveness.
6. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

7. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
8. The Chair then thanked the experts, ERG and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

9. The committee discussed confidential information submitted as part of this appraisal.
10. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
11. The committee decision was based on consensus.
12. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.